Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Invested Capital (2016 - 2026)

Akebia Therapeutics has reported Invested Capital over the past 11 years, most recently at $80.9 million for Q4 2025.

  • Quarterly Invested Capital rose 870.68% to $80.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.9 million through Dec 2025, up 870.68% year-over-year, with the annual reading at $80.9 million for FY2025, 870.68% up from the prior year.
  • Invested Capital was $80.9 million for Q4 2025 at Akebia Therapeutics, down from $89.2 million in the prior quarter.
  • Over five years, Invested Capital peaked at $213.9 million in Q1 2021 and troughed at -$31.4 million in Q3 2023.
  • The 5-year median for Invested Capital is $72.8 million (2022), against an average of $69.9 million.
  • Year-over-year, Invested Capital crashed 355.96% in 2024 and then skyrocketed 2362.49% in 2025.
  • A 5-year view of Invested Capital shows it stood at $171.6 million in 2021, then crashed by 58.43% to $71.3 million in 2022, then crashed by 94.25% to $4.1 million in 2023, then tumbled by 355.96% to -$10.5 million in 2024, then skyrocketed by 870.68% to $80.9 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Invested Capital are $80.9 million (Q4 2025), $89.2 million (Q3 2025), and $76.3 million (Q2 2025).